Columvi
Columvi ingredients
| Active ingredient | Strength |
|---|---|
| Glofitamab | 10 mg/10mL, 2.5 mg/2.5mL |
What Columvi is used for
The FDA lists the approved uses on the official label (below). In the EU, glofitamab is approved as Columvi for:
Columvi in combination with gemcitabine and oxaliplatin is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are ineligible for autologous stem cell transplant (ASCT).Columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL), after two or more lines of systemic therapy.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Columvi
- Generic name
- Glofitamab
- Made by
- Genentech, Inc.
- Forms
- Concentrate, Solution, Concentrate
- Given
- Intravenous
- Drug class
- Bispecific CD20-directed CD3 T Cell Engager
- FDA approval
- Biologic licence (BLA) BLA761309
- On the US market since
- 2023
Official information
- Columvi prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Glofitamab)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Columvi?
Columvi (Glofitamab) is a cancer medicine made by Genentech, Inc., approved by the US FDA.
What are the ingredients of Columvi?
Columvi contains Glofitamab (10 mg/10mL, 2.5 mg/2.5mL).
Is Columvi approved in Europe?
The same active substance is approved in the EU as Columvi.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA